The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InTG Therapeutics (TGTX) continues to demonstrate significant momentum as sales for its Multiple Sclerosis treatment, BRIUMVI, reached $594 million in the U.S. during 2025. This performance represents a substantial 90% year-over-year increase, highlighting rapid market adoption and robust demand. Looking ahead, the company has issued optimistic guidance for 2026, forecasting revenues between $825 million and $850 million. Investors are also focused on upcoming clinical milestones, including the Phase 3 ENHANCE study results and the development of a subcutaneous version of the drug. These advancements could further expand the company's competitive edge and market share. Consequently, analysts maintain a 'Strong Buy' rating based on this consistent growth trajectory and promising clinical pipeline.